|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1175 USD | -1.26% |
|
+0.34% | +657.96% |
| 07-28 | Sunshine Biopharma Receives Health Canada Approval for Generic Ondansetron to Treat Chemotherapy-Induced Nausea | MT |
| 06-25 | Sunshine Biopharma Secures Approval for Generic Anastrozole in Canada | MT |
| Market Cap | 2.61M 2.26M 2.11M 1.94M 3.64M 249M 3.7M 24.76M 9.72M 125M 9.81M 9.59M 412M | P/E 2026 * |
-0.2x | P/E 2027 * | 6.15x |
|---|---|---|---|---|---|
| Enterprise Value | 2.61M 2.26M 2.11M 1.94M 3.64M 249M 3.7M 24.76M 9.72M 125M 9.81M 9.59M 412M | EV / Sales 2026 * |
0.07x | EV / Sales 2027 * | 0.06x |
| Free-Float |
99.57% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -1.26% |
| Manager | Title | Age | Since |
|---|---|---|---|
Steve Slilaty
CEO | Chief Executive Officer | 74 | 2009-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 65 | 2009-10-14 |
Michel Roy
PRN | Corporate Officer/Principal | 58 | 2025-01-14 |
| Director | Title | Age | Since |
|---|---|---|---|
Steve Slilaty
CHM | Chairman | 74 | 2009-10-14 |
Camille Sebaaly
BRD | Director/Board Member | 65 | 2025-12-10 |
Rabi Kiderchah
BRD | Director/Board Member | 53 | 2021-10-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.26% | +0.34% | - | - | 2.61M | |
| -0.52% | +3.21% | +89.52% | +127.32% | 1,057B | |
| +0.88% | +1.13% | +49.56% | +49.69% | 625B | |
| +0.89% | -1.95% | +24.23% | +64.44% | 435B | |
| +0.71% | +3.87% | +49.07% | +37.85% | 363B | |
| +0.64% | -0.49% | +33.94% | +40.01% | 296B | |
| +0.39% | -5.83% | +8.92% | +7.85% | 249B | |
| +1.51% | +6.69% | +42.58% | +57.57% | 222B | |
| +3.92% | -0.46% | -5.56% | -52.32% | 209B | |
| +1.80% | +2.30% | +11.56% | +66.35% | 165B | |
| Average | +0.90% | +0.87% | +33.76% | +44.31% | 402.31B | |
| Weighted average by Cap. | +0.66% | +1.22% | +48.72% | +64.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 35.39M 30.61M 28.59M 26.22M 49.32M 3.37B 50.11M 335M 132M 1.69B 133M 130M 5.58B | 45M 38.92M 36.35M 33.35M 62.72M 4.28B 63.72M 426M 167M 2.15B 169M 165M 7.1B |
| Net income | -3.15M -2.72M -2.54M -2.33M -4.39M -300M -4.46M -29.83M -11.71M -150M -11.82M -11.56M -496M | 102K 88.66K 82.8K 75.95K 143K 9.76M 145K 971K 381K 4.89M 385K 376K 16.16M |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.230USD
Average target price
56.00USD
Spread / Average Target
+4,452.85%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SBFM Stock
- SBFM Stock
Select your edition
All financial news and data tailored to specific country editions
